Daily Stock Analysis, DERM, Dermira Inc, priceseries

Dermira Inc. Daily Stock Analysis
Stock Information
Open
7.46
Close
7.07
High
7.46
Low
7.01
Previous Close
7.46
Daily Price Gain
-0.39
YTD High
8.08
YTD High Date
Feb 15, 2019
YTD Low
6.00
YTD Low Date
Jan 25, 2019
YTD Price Change
-0.30
YTD Gain
-4.07%
52 Week High
27.83
52 Week High Date
Feb 27, 2018
52 Week Low
6.00
52 Week Low Date
Jan 25, 2019
52 Week Price Change
-19.67
52 Week Gain
-73.56%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 6. 2017
24.20
Sep 22. 2017
26.32
12 Trading Days
8.75%
Link
LONG
Dec 6. 2017
24.70
Jan 2. 2018
27.18
17 Trading Days
10.03%
Link
LONG
May 4. 2018
9.51
May 21. 2018
10.35
11 Trading Days
8.84%
Link
LONG
Jun 6. 2018
9.27
Jun 25. 2018
10.03
13 Trading Days
8.16%
Link
LONG
Jul 6. 2018
9.91
Jul 17. 2018
10.67
7 Trading Days
7.64%
Link
LONG
Sep 26. 2018
10.59
Oct 10. 2018
11.78
10 Trading Days
11.26%
Link
Company Information
Stock Symbol
DERM
Exchange
NasdaqGS
Company URL
http://www.dermira.com
Company Phone
650 421 7200
CEO
Thomas G. Wiggans
Headquarters
California
Business Address
275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001557883
About

Dermira, Inc. is a biopharmaceutical company that focuses on bringing differentiated products to dermatologists and patients. It also focuses on medical dermatology, a field that concentrates on therapeutic solutions to treat skin conditions, such as psoriasis, hyperhidrosis and acne. Dermira was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Menlo Park, CA.

Description

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.